First and second pregnancy outcomes in women with class III obesity: An observational cohort study.

Obes Res Clin Pract

Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Little France Drive, Edinburgh, United Kingdom. Electronic address:

Published: September 2021

Introduction: Class III obesity (BMI ≥ 40 kg/m) during pregnancy predisposes mother and offspring to a range of adverse pregnancy complications and outcomes. Risk profiles vary between pregnancies and are affected by interpregnancy weight gain. We evaluated the risk of adverse outcomes in women with BMI ≥ 40 kg/m in first and second pregnancies, and the impact of interpregnancy weight change on this risk.

Materials And Methods: Data were extracted for all women with BMI ≥ 40 kg/m at first antenatal visit, who completed antenatal and delivery care for first and second pregnancies in NHS Lothian between 1/1/2009-31/12/2018. Multiple pregnancies and recipients of bariatric surgery were excluded.

Results: 442 pregnancies among 221 women were included. In first pregnancy, median (interquartile range) weight was 117 kg (108.5-126.7), age 28 years (24-31) and BMI 42 kg/m (41.0-44.5), 14.4% had gestational diabetes (GDM), 11.3% had pregnancy-induced hypertension and 44.6% had a post-partum haemorrhage (PPH). 20.8% of babies were large for gestational age (LGA, ≥97% centile at birth). In second pregnancy, women were heavier with a median weight of 119.9 kg (109.0-130.0, p = 0.00) with 19.9% gaining over 10 kg. Women were more likely to develop GDM (21.6%, p = 0.02). Babies were heavier with 40% of babies LGA (p < 0.0001). Interpregnancy weight change had no significant impact on GDM, pregnancy induced hypertension, PPH, perinatal mortality or LGA.

Conclusions: In a population of women with BMI ≥ 40 kg/m, pregnancy complications are common and risk is higher in second pregnancy. The interpregnancy period is a critical time to engage women in health improvement and weight loss strategies to maximise outcomes for mother and offspring.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.orcp.2021.05.004DOI Listing

Publication Analysis

Top Keywords

bmi ≥
16
≥ kg/m
16
second pregnancy
12
interpregnancy weight
12
women bmi
12
women
8
outcomes women
8
class iii
8
iii obesity
8
kg/m pregnancy
8

Similar Publications

Objective: Enhanced Recovery After Surgery (ERAS) clinical pathways have demonstrated improved perioperative outcomes after major surgery. However, its adoption within vascular surgery has been limited. In this study, we examined the impact of an ERAS protocol with multimodal anesthesia on open abdominal aortic aneurysm (AAA) repair by comparing early outcomes before and after its implementation.

View Article and Find Full Text PDF

HIGH BODY MASS INDEX IS ASSOCIATED WITH LOWER ADALIMUMAB SERUM LEVELS AND HIGHER DISEASE ACTIVITY IN NON-INFECTIOUS UVEITIS.

Am J Ophthalmol

December 2024

Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Purpose: Adalimumab, a TNF-alpha inhibitor, is the only FDA-approved biologic for non-infectious uveitis (NIU). However, treatment responses vary, potentially due to interindividual pharmacokinetic differences influenced by body mass index (BMI). This study aimed to evaluate the impact of BMI on adalimumab serum trough levels and therapeutic efficacy in patients with NIU.

View Article and Find Full Text PDF

Aim: The early diagnosis of atherosclerotic changes to prevent ischemic events represents a clinical challenge.Prostate-specific membrane antigen (PSMA) as an established diagnostic in the field of prostate cancer also appears to detect neovascularization and inflammation in other diseases. We hypothesized that it might be also suited for detection of inflammation in atherosclerosis.

View Article and Find Full Text PDF

Background: Liraglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP1RA), is a well-established anti-diabetic drug, has also been approved for the treatment of obesity at a dose of 3 mg. There are a limited number of studies in the literature that have looked at changes in metabolite levels before and after liraglutide treatment in patients with obesity. To this end, in the present study we aimed to explore the changes in the plasma metabolomic profile, using liquid chromatography-high resolution mass spectrometry (LC-HRMS) in patients with obesity.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored the effects of the GLP-1 receptor agonist liraglutide on plasma protein profiles in patients with obesity, finding significant changes in weight, BMI, and HbA1c after three months of treatment.
  • A total of 151 proteins showed significant dysregulation, with 31 being upregulated and 120 downregulated post-treatment, highlighting potential biomarkers like Cystatin-B and multimerin-2.
  • Pathway analysis revealed major signaling pathways involved, particularly MAPK, AKT, and PKc, which play a crucial role in cell communication and could inform future obesity treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!